皮膚軟組織感染：萬古黴素支配的時代結束 是由出版商Datamonitor在2009年07月所出版的。
這份英文市場調查報告書價格從美金3800起跳。
醫師們認為美國甲氧苯青黴素抗藥性黄色葡萄球菌是擴散及地區傳染的最重要病原體。
本報告書內容包括：主要病原體的流行病學動向及經濟影響、診斷及介紹概要、主要開發藥物概要及未來的潛在需求、醫院及地區治療方法概要等。內容綱要摘記如下：
實施概要
流行病學及疾病概要
- 病因及症狀
- 皮膚軟組織感染的種類
- 併發症及非併發症
- 病原體
- 風險類群
- 流行病學動向
- 門診醫療利用的促進因素
- 美國
- 與美國、歐洲的甲氧苯青黴素抗藥性黄色葡萄球菌感染率相比，日本較低
- 歐洲
- 皮膚軟組織感染造成的經濟負擔
發現、診斷、介紹
- 概要
- 發現
- 診斷
- 介紹
- 皮膚軟組織感染診斷的潛在需求及未來動向
現在的治療方法及動向
- 市場概要
- 治療指南
- 治療方法
- 皮膚軟組織感染的抗藥性問題
- 治療方法之選擇
潛在需求及新發展
- 潛在需求及未來發展
- 法律許可是開發皮膚軟組織感染治療藥製藥企業的大課題
- 各種治療特色有助於抗細菌藥的攝取
- 治療滿意度
- 皮膚軟組織感染治療的潛在需求
- 針對皮膚軟組織感染的開發藥物產品線
參考資料
附錄
Abstract
Introduction
Treatment of skin and skin structure infections often requires systemic
antibacterial therapy. Two trends are concerning physicians: the spread of
methicillin-resistant Staphylococcus aureus (MRSA), particularly
community-acquired strains (CA-MRSA) have become the most important pathogen
in the US; and a slow but measurably declining susceptibility to vancomycin by
these bacteria.
Scope of this research
- Epidemiological trends and economic impact of key pathogens
- Overview of diagnosis and referral patterns
- Analysis of present and future unmet needs with outline of key drugs in
development for SSTIs
- Outline of drivers of treatment choice in both the hospital and the
community setting
Research and analysis highlights
Guideline adoption for skin and soft tissue infections (SSTIs) among
specialists is fairly strong, but less so among primary care physicians
(PCPs). PCPs treat mild-to-moderate forms of disease, representing an
estimated 70% of SSTI patients, while specialists treat severe SSTI sufferers
(30%).
Resistance is the single most important factor affecting the SSTI drug market,
in both the community and hospital settings. Vancomycin has traditionally been
viewed as the most effective treatment option for SSTIs caused by MRSA,
although bacterial resistance to the drug is emerging and it is becoming less
effective for the treatment of SSTIs.
A highly valuable new SSTI drug should possess a number of important
characteristics, including strong bactericidal activity against MRSA, VISA,
and H-VISA strains, a good toxicity and side effect profile,
cost-effectiveness, good tissue penetration for systemic use, superior
efficacy versus vancomycin, and broad spectrum coverage.
Key reasons to purchase this research
- Identify key opportunities that will impact the use and uptake of new and
existing products
- Understand the critical issues that drive prescription choice in skin and
soft tissue infections
- Learn about the difference between key antibacterial drug attributes
relevant to hospital and community-based physicians
Table of Contents
EXECUTIVE SUMMARY
- Scope of the analysis
- Datamonitor insight into the skin and soft tissue infections market
- Contributing experts
- Related reports
- Upcoming related reports
EPIDEMIOLOGY AND DISEASE BACKGROUND
- Etiology and symptoms
- Types of skin and soft tissue infections
- Complicated and uncomplicated skin and soft tissue infections
- Pathogens
- Risk groups
- Epidemiological trends
- SSTIs are a major driver for ambulatory care utilization
- US
- Incidence of MRSA is lower in Japan compared to the US and Europe
- Europe
- Economic burden of skin and soft tissue infections
PRESENTATION, DIAGNOSIS AND REFERRAL OPTIONS
- Overview
- Presentation
- Diagnosis
- Diagnosis of skin and soft tissue infections is commonly based purely on
clinical impression
- Guidelines for the diagnosis and management of skin and soft tissues
infections are sparse across the seven major markets
- Laboratory tests used in the diagnosis of skin and soft tissue infections
- Referral
- Primary care physicians treat most skin and soft tissue infections,
although a referral may be made in more severe cases
- Reasons for hospital admission for SSTIs
- Mild-to-moderate nosocomial skin and soft tissue infections are treated
by the attending physician
- Unmet needs and future developments in the diagnosis of skin and soft
tissue infections
- Cepheid has developed a rapid molecular diagnostic test for SSTIs caused
by MRSA and methicillin-susceptible S. aureus
CURRENT TREATMENT OPTIONS AND TRENDS
- Market overview
- Treatment guidelines
- Guideline adherence for SSTIs is strong among specialists, but poor
among primary care physicians
- Treatment options
- Current skin and soft tissue infection therapies
- Resistance issues for skin and soft tissue infections
- Resistance issues are growing for bacterial skin and soft tissue
infections caused by staphylococci and streptococci
- Studies and key opinion leaders acknowledge that vancomycin is becoming
less effective at treating SSTIs caused by MRSA
- Emerging pathogens
- Treatment choice
- Efficacy against pathogens is highly influential in treatment choice for
skin and soft tissue infections, although safety and cost also play a role
UNMET NEEDS AND NEW DEVELOPMENTS
- Unmet needs and future developments
- Gaining regulatory approval represents a significant challenge for
pharmaceutical companies developing drugs for the treatment of skin and soft
tissue infections
- The different characteristics of therapies can all contribute to the
uptake of new antibacterial drugs for SSTIs
- Treatment satisfaction
- Unmet needs in the treatment of skin and soft tissue infections
- Key pipeline drugs in development for skin and soft tissue infections
- Telavancin
- Ceftobiprole
- Oritavancin
- Ceftaroline
- Iclaprim
- Torezolid
- Dalbavancin
- Radezolid (RX-1741)
- Delafloxacin (RX-331)
- Razupenem (PZ-601)
BIBLIOGRAPHY
APPENDIX A
APPENDIX B
TABLES
- Table: Occurrence of pathogens causing skin and soft tissue infections in
North America, Europe, Latin America, and Asia-Pacific region, 1999 - 2004
- Table: Occurrence of pathogens responsible for causing skin and soft
tissue infections in the US and Canada, 1997 - 2000
- Table: Etiologic risk factors for skin and soft tissue infections and
their associated bacterial causes
- Table: Drug susceptibilities of methicillin-susceptible Staphylococcus
aureus isolated from SSTI outpatients across the US, France, Germany, Italy,
and Spain, 2001
- Table: Drug susceptibilities of methicillin-resistant Staphylococcus
aureus isolated from SSTI outpatients across the US, France, Germany, Italy,
and Spain, 2001
- Table: Drug susceptibilities of methicillin-susceptible Staphylococcus
aureus isolated from SSTI inpatients and intensive care unit patients across
the US, France, Germany, Italy, and Spain, 2001
- Table: Drug susceptibilities of methicillin-resistant Staphylococcus
aureus isolated from SSTI inpatients and intensive care unit patients across
the US, France, Germany, Italy, and Spain, 2001
- Table: Drug susceptibilities of Streptococcus pyogenes isolated from SSTI
inpatients and intensive care unit patients across the US, France, Germany,
Italy, and Spain, 2001
- Table: Vancomycin susceptibility results for Staphylococcus aureus
isolates across the five major EU markets, 2001 - 06
- Table: Importance of different characteristics of drugs in treatment
choice in both the community and hospital settings
|
